Bayesian Analysis Supports Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Rizzo, Alessandro; Ricci, Angela Dalia; Brandi, Giovanni

doi:10.1159/000520481

Cited by 3 publications

(1 citation statement)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, several recent studies and clinical trials have shown that immunotherapy or combination immunotherapy has the potential to improve the prognosis of patients with advanced LIHC ( Rizzo et al, 2021 ; Rizzo et al, 2022a ). In patients with unresectable untreated LIHC, disease-free survival (DFS) and overall survival (OS) are significantly longer with combination ICB, and there is greater hope that patients will undergo subsequent surgery ( Rizzo and Brandi, 2021 ; Rizzo et al, 2022b ). Our previous study has identified several biomarkers that predict the response to ICB treatment in LIHC patients, including TUBA1B ( Hu et al, 2022a ), TUBA1C ( Hu et al, 2022b ), and KIFC1 ( Li et al, 2021 ).…”

Section: Introductionmentioning

confidence: 99%

Transmembrane and coiled-coil domains 3 is a diagnostic biomarker for predicting immune checkpoint blockade efficacy in hepatocellular carcinoma

Zhu²,

Shan³

et al. 2022

Front. Genet.

View full text Add to dashboard Cite

Liver hepatocellular carcinoma (LIHC) is a malignancy with a high mortality and morbidity rate worldwide. However, the pathogenesis of LIHC has still not been thoroughly studied. Transmembrane and coiled-coil domains 3 (TMCO3) encodes a monovalent cation, a member of the proton transducer 2 (CPA2) family of transporter proteins. In the present study, TMCO3 expression and its relationship with cancer prognosis, as well as its immunological role in LIHC were studied by bioinformatic analysis. We found the significant overexpression of TMCO3 in LIHC in the TCGA, HCCDB, and GEO databases. In LIHC patients, high TMCO3 expression was related to poorer overall survival (OS) and TMCO3 had good predictive accuracy for prognosis. Moreover, TMCO3 was linked to the infiltrates of certain immune cells in LIHC. The correlation of TMCO3 with immune checkpoints was also revealed. Moreover, patients with LIHC with low TMCO3 expression showed a better response to immune checkpoint blockade (ICB) than those with LIHC with high TMCO3 expression. GO and KEGG enrichment analyses indicated that TMCO3 was probably involved in the microtubule cytoskeleton organization involved in mitosis, small GTPase mediated signal transduction, and TGF-β pathway. In conclusion, TMCO3 may be a potential biomarker for LIHC prognosis and immunotherapy.

show abstract